Document is current
Any future updates will be listed below
-
Authors
He, Bailin
Lin, Ren
Xu, Na
Qin, Le
Wang, Zhixiang
Wang, Qiang
Li, Xiaofang
Wei, Xiaolei
Wei, Yongqiang
Tang, Zhaoyang
Fan, Zhiping
Huang, Fen
Liu, Xiaoli
Sun, Jing
Xuan, Li
Li, Peng
Zhou, Hongsheng
Liu, Qifa https://orcid.org/0000-0003-4015-3952
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04605666 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial
https://doi.org/10.1186/s12967-025-06608-x
-
Funding
Funding for this research was provided by:
Major Program of National Natural Science Foundation of China (82293634)
National Natural Science Foundation of China (82300252, 82470171, 81970161, 82170163, 81970147)
Basic and Applied Basic Research Foundation of Guangdong Province (2022A1515110828)
China Postdoctoral Science Foundation (2022M721498)
- License Information
-
More Information
Article History
Received: 9 March 2025
Accepted: 12 May 2025
First Online: 27 May 2025
Declarations
:
: This study involves human participants and was approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University (Approval No. NFEC-2020-098). Participants gave informed consent to participate in the study before taking part.
: All subjects provided written informed consent before enrollment and samples and data from patients were processed following standard operating procedures approved by the Medical Ethics Committee of Nanfang Hospital of Southern Medical University.
: The authors declare no competing interests.
